Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Future Medicine Ltd.
Abstract
Talazoparib is an oral PARP inhibitor approved for locally advanced/metastatic breast cancer. There is no consensus, however, as to whether it is better used as a first-line treatment or after other therapies in patients with gBRCA mutations. In fact, talazoparib showed its superiority compared with chemotherapy in the survival and quality of life of patients with BRCA mutations, with an acceptable toxicity profile. While its role in this indication is not debated, its cost as well as the availability of other effective new agents, particularly immune checkpoint inhibitors, may encourage the movement of this drug to later treatment lines. Until more robust data are available, the best treatment sequence for BRCA-mutated breast cancer must be personalized on a case-by-case basis. © 2022 Future Medicine Ltd.
Description
Keywords
Brca mutation, Breast cancer, Parp inhibitors, Talazoparib, Brca1 protein, Breast neoplasms, Female, Humans, Phthalazines, Quality of life, Antineoplastic agent, Immune checkpoint inhibitor, Nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor, Phthalazine derivative, Advanced cancer, Article, Blood toxicity, Brca gene, Cancer patient, Cancer survival, Cancer survivor, Central nervous system metastasis, Clinical trial (topic), Consensus, Cytopenia, Disease duration, Disease free survival, Disease management, Drug cost, Drug efficacy, Drug tolerability, Family history, Gene, Gene mutation, High risk patient, Human, Human epidermal growth factor receptor 2 negative breast cancer, Overall survival, Patient selection, Personalized medicine, Physician, Prevalence, Progression free survival, Statistical analysis, Subgroup analysis, Trend study, Triple negative breast cancer, Breast tumor, Genetics, Pathology